Abstract
In this issue of Molecular Therapy, the safe application of a cancer vaccine based on self-amplifying Semliki Forest virus (SFV) RNA replicon particles was recently demonstrated by Komdeur et al.1 in the first-in-human phase I clinical trial for the treatment of human papillomavirus (HPV)-induced cancers. The study showed both CD4+ and CD8+ T cell responses in all immunized subjects. These findings are encouraging, but, for the “hardcore” alphavirus enthusiast, not surprising and rather frustrating because it took so long.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
